All In Biotech

Drug Trial Radar · NCT07818070

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

A Phase 3, Randomized, Multicenter, Double-blind Study of the Efficacy and Safety of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With HER2-negative, PD-L1-Positive Advanced or Metastatic Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Jan 2031

Study completion Jan 2031

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Deciphera Pharmaceuticals, LLC
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ONO-4578 in combination nivolumab and chemotherapy in participants with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. Participants will: * Receive either ONO-4578 with nivolumab and chemotherapy or placebo with nivolumab and chemotherapy. * Make visits to the clinic for checkups and tests. * Answer questions about their health throughout the trial.

Conditions

  • Gastric Cancer
  • Esophagogastric Junction Cancer
  • Esophageal Adenocarcinoma

Interventions

  • ONO-4578Drug

    ONO-4578 will be administered to participants at a specified dose once daily.

  • PlaceboOther

    Matching placebo for ONO-4578 will be administered to participants once daily.

  • NivolumabDrug

    Nivolumab will be administered to participants at a specified dose on specified days.

  • OxaliplatinDrug

    Oxaliplatin will be administered to participants at a specified dose on specified days.

  • CapecitabineDrug

    Capecitabine will be administered to participants at a specified dose on specified days.

  • Tegafur-gimeracil-oteracil potassium (S-1)Drug

    S-1 will be administered to participants at a specified dose on specified days.

  • FluorouracilDrug

    Fluorouracil will be administered to participants at a specified dose on specified days.

  • Leucovorin CalciumDrug

    Leucovorin Calcium will be administered to participants at a specified dose on specified days.

  • LevoleucovorinDrug

    Levoleucovorin will be administered to participants at a specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 4 years
  2. Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Time frame: Up to approximately 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.